Key facts
- Geltor’s last known valuation is $462.9M (Feb 2022).
- It has raised $112.8M; the latest was Later Stage VC in Aug 2025.
- Notable investors include SOSV, BoxGroup, IndieBio, Texas Medical Center, Pegasus Tech Ventures — 44 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 44 names
- ·Watchlist + deal alerts for Geltor
- ·The full record, as it builds
Funding rounds
No funding rounds for Geltor are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Geltor
Producer of bespoke animal-free proteins intended to advance protein innovation. The company's products feature a proprietary AI that designs novel proteins by narrowing down amino acid sequences from extended possibilities, creating customized proteins for industries focused on beauty, health, and other applications that require specialized proteins tailored to specific functional and commercial requirements, enabling businesses to make products sustainably and grow towards a plant-based future.
- Sector
- Healthcare
- HQ
- Emeryville, CA, United States
- Founded
- 2015
- Employees
- 50
- Website
- geltor.com/
- Ownership
- Privately Held (backing)
Geltor doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Geltor shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Geltor in its N-PORT filings yet. We sweep new filings monthly.